INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Soleno Therapeutics, Inc. ( NASDAQ: SLNO ) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm - Soleno Therapeutics ( NASDAQ:SLNO )
NEWTOWN, Pa., Nov. 16, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Soleno Therapeutics, Inc. ( "Soleno" or "the Company" ) ( NASDAQ:SLNO ) , resulting from allegations of providing potentially ...
SLNO INVESTIGATION ALERT: Investigation Launched into Soleno Therapeutics, Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - RGRD Law - Soleno Therapeutics ( NASDAQ:SLNO )
SAN DIEGO, Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc. ( NASDAQ:SLNO ) focused on whether Soleno and certain of its executives made false and/or ...
Soleno Therapeutics ( SLNO ) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% - Hagens Berman - Soleno Therapeutics ( NASDAQ:SLNO )
SAN FRANCISCO, Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Investors in Soleno Therapeutics, Inc. ( NASDAQ:SLNO ) saw the price of their shares tumble $18.78 ( -28% ) after the company reported disappointing information about VYKAT™ XR, a once-daily oral tablet intended to treat hyperphagia.
Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. ( SLNO ) Shareholders Who Have Incurred Losses - Soleno Therapeutics ( NASDAQ:SLNO )
SAN DIEGO, Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. ( NASDAQ:SLNO ) or certain of its officers and directors violated federal securities laws by making false or misleading statements and/or failing to ...
Why Is Soleno Therapeutics Stock Surging Tuesday? - Soleno Therapeutics ( NASDAQ:SLNO )
Soleno Therapeutics Inc. ( NASDAQ:SLNO ) stock rose Tuesday after the company said its board had approved a share repurchase program and entered into a $100 million accelerated share repurchase ( ASR ) agreement with Jefferies Financial Group Inc.'s ( NYSE:JEF ) Jefferies LLC to buy back its ...
PubMatic Posts Upbeat Q3 Results, Joins Energy Vault, RealReal And Other Big Stocks Moving Higher On Tuesday - BigBear.ai Hldgs ( NYSE:BBAI ) , Clearwater Analytics Hldg ( NYSE:CWAN )
U.S. stocks were mixed, with the Dow Jones index gaining more than 100 points on Tuesday. Shares of PubMatic Inc ( NASDAQ:PUBM ) rose sharply after the company reported better-than-expected third-quarter financial results.
Bragar Eagel & Squire, P.C. Is Investigating Agilon, Soleno, Avita, and Coty and Encourages Investors to Contact the Firm - Agilon Health ( NYSE:AGL ) , Coty ( NYSE:COTY )
NEW YORK, Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agilon Health, Inc. ( NYSE:AGL ) , Soleno Therapeutics, Inc. ( NASDAQ:SLNO ) , AVITA Medical, Inc. ( NASDAQ:RCEL ) , and Coty, ...
Super Micro Computer Posts Downbeat Q1 Results, Joins Pinterest, Axon Enterprise And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Arista Networks ( NYSE:ANET ) , Advanced Micro Devices ( NASDAQ:AMD )
U.S. stock futures were lower this morning, with the Dow futures falling more than 50 points on Wednesday. Shares of Super Micro Computer Inc ( NASDAQ:SMCI ) fell sharply in pre-market trading after the company reported worse-than-expected first-quarter financial results and issued second-quarter ...
Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Akari Therapeutics ( NASDAQ:AKTX ) , Applied Digital ( NASDAQ:APLD )
Shares of Teradata Corp ( NYSE:TDC ) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results and raised its FY25 EPS guidance above estimates. Also, the company issued fourth-quarter EPS guidance above estimates.
Soleno Therapeutics to Participate in Upcoming November Conferences
REDWOOD CITY, Calif., Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( "Soleno" ) ( NASDAQ: SLNO ) , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in ...
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. ( NASDAQ: SLNO ) , You Are Encouraged to Contact The Rosen Law Firm About Your Rights - Soleno Therapeutics ( NASDAQ:SLNO )
NEW YORK, Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. ( NASDAQ:SLNO ) resulting from allegations that Soleno Therapeutics may have issued ...
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
AUSTIN, Texas, Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Cassava Sciences, Inc. ( NASDAQ: SAVA, "Cassava", the "Company" ) , a biotechnology company focused on developing novel, investigational treatments for central nervous system ( CNS ) disorders such as Tuberous Sclerosis Complex ( TSC ) -related ...
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors - Cassava Sciences ( NASDAQ:SAVA )
AUSTIN, Texas, Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Cassava Sciences, Inc. ( NASDAQ:SAVA, "Cassava", the "Company" ) ) , a biotechnology company focused on developing novel, investigational treatments for central nervous system ( CNS ) disorders such as Tuberous Sclerosis Complex ( TSC ) -related ...
ROSEN, A TOP RANKED LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO
ROSEN, A TOP RANKED LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation ...
Soleno Therapeutics ( SLNO ) Drops Amid Critical Scorpion Report -- Hagens Berman - Soleno Therapeutics ( NASDAQ:SLNO )
SAN FRANCISCO, Oct. 09, 2025 ( GLOBE NEWSWIRE ) -- On August 15, 2025, shares in Soleno Therapeutics, Inc. ( NASDAQ:SLNO ) experienced a significant drop following the release of a highly critical report by Scorpion Capital.
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Soleno Therapeutics, Inc. - SLNO - Soleno Therapeutics ( NASDAQ:SLNO )
NEW YORK, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ( "Soleno" or the "Company" ) SLNO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short - ACADIA Pharmaceuticals ( NASDAQ:ACAD )
Acadia Pharmaceuticals Inc. ACAD released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin ( ACP-101 ) in patients with hyperphagia in Prader-Willi syndrome ( PWS ) .
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm - Soleno Therapeutics ( NASDAQ:SLNO )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno ( SLNO ) To Contact Him Directly To Discuss Their Options Click here to participate in the action. NEW YORK, Sept. 18, 2025 ( GLOBE NEWSWIRE ) --
Soleno Therapeutics ( SLNO ) Drops Amid Critical Scorpion Report -- Hagens Berman - Soleno Therapeutics ( NASDAQ:SLNO )
SAN FRANCISCO, Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- On August 15, 2025, shares in Soleno Therapeutics, Inc. SLNO experienced a significant drop following the release of a highly critical report by Scorpion Capital. Hagens Berman, a national shareholders rights firm, has opened an ...
Soleno Therapeutics ( SLNO ) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Soleno Therapeutics (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO - Soleno Therapeutics ( NASDAQ:SLNO )
NEW YORK, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ( "Soleno" or the "Company" ) SLNO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Unpacking the Latest Options Trading Trends in Soleno Therapeutics - Soleno Therapeutics ( NASDAQ:SLNO )
Deep-pocketed investors have adopted a bearish approach towards Soleno Therapeutics SLNO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm - Soleno Therapeutics ( NASDAQ:SLNO )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno ( SLNO ) To Contact Him Directly To Discuss Their Options
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. ( NASDAQ: SLNO ) , You Are Encouraged to Contact The Rosen Law Firm About Your Rights - Soleno Therapeutics ( NASDAQ:SLNO )
NEW YORK, Sept. 07, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc.
Bragar Eagel & Squire, P.C. Is Investigating Fortinet, Roblox, Soleno, and Simulations Plus and Encourages Investors to Contact the Firm - Fortinet ( NASDAQ:FTNT ) , Roblox ( NYSE:RBLX )
NEW YORK, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fortinet, Inc. FTNT, Roblox Corporation RBLX, Soleno Therapeutics, Inc. SLNO, and Simulations Plus, Inc.
Soleno Therapeutics to Participate in Upcoming September Conferences
REDWOOD CITY, Calif., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( "Soleno" ) ( NASDAQ: SLNO ) , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in ...
Soleno Therapeutics ( SLNO ) Drops Amid Critical Scorpion Report -- Hagens Berman - Soleno Therapeutics ( NASDAQ:SLNO )
SAN FRANCISCO, Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- On August 15, 2025, shares in Soleno Therapeutics, Inc. SLNO experienced a significant drop following the release of a highly critical report by Scorpion Capital. Hagens Berman, a national shareholders rights firm, has opened an investigation ...
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm - Soleno Therapeutics ( NASDAQ:SLNO )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno ( SLNO ) To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO - Soleno Therapeutics ( NASDAQ:SLNO )
NEW YORK, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ( "Soleno" or the "Company" ) SLNO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Investigation of Soleno Therapeutics, Inc. ( SLNO ) Announced by Holzer & Holzer, LLC - Soleno Therapeutics ( NASDAQ:SLNO )
ATLANTA, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Holzer & Holzer, LLC is investigating whether Soleno Therapeutics, Inc. ( "Soleno Therapeutics" or the "Company" ) SLNO complied with federal securities laws.
Down 21.7% in 4 Weeks, Here's Why Soleno Therapeutics ( SLNO ) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Soleno Therapeutics (SLNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
Soleno Therapeutics ( SLNO ) Drops Amid Critical Scorpion Report -- Hagens Berman - Soleno Therapeutics ( NASDAQ:SLNO )
SAN FRANCISCO, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- On August 15, 2025, shares in Soleno Therapeutics, Inc. SLNO experienced a significant drop following the release of a highly critical report by Scorpion Capital. Hagens Berman, a national shareholders rights firm, has opened an investigation ...
Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe - Soleno Therapeutics ( NASDAQ:SLNO )
SLNO shares fall 9.68% after Scorpion Capital calls Vykat XR unsafe and overpriced. The report warns that Soleno's stock could drop back to penny-stock territory. Get the latest proven ETF strategies to target and profit from summer volatility before the next big market swing.
How Much Upside is Left in Soleno Therapeutics ( SLNO ) ? Wall Street Analysts Think 43.15%
The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Soleno Therapeutics (SLNO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Momentum in Soleno Therapeutics ( SLNO ) Should Keep going
Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Soleno ( SLNO ) Q2 Revenue Jumps 30%
Soleno Therapeutics ( NASDAQ:SLNO ) , a biotech company focused on rare disease treatments, posted its inaugural commercial revenue following the U.S. launch of VYKAT XR for Prader-Willi syndrome ( PWS ) . In its earnings release on August 6, 2025, the company reported GAAP revenue of $32.7 ...
Soleno Therapeutics, Inc. ( SLNO ) Reports Q2 Loss, Tops Revenue Estimates
Soleno Therapeutics (SLNO) delivered earnings and revenue surprises of +83.02% and +1.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Soleno Therapeutics, Inc. ( SLNO ) is a Great Momentum Stock: Should You Buy?
Does Soleno Therapeutics, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Can Soleno Therapeutics ( SLNO ) Climb 33.11% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Soleno Therapeutics (SLNO) points to a 33.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's What Could Help Soleno Therapeutics ( SLNO ) Maintain Its Recent Price Strength
If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., July 10, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) SLNO, a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering of 2,352,941 ...
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
REDWOOD CITY, Calif., July 10, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) ( Nasdaq: SLNO ) , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering ...
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock
REDWOOD CITY, Calif., July 10, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) ( Nasdaq:SLNO ) , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell $200 million of shares of its common ...
Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025
REDWOOD CITY, Calif., July 10, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) ( Nasdaq: SLNO ) , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today certain preliminary unaudited financial and operational results for the ...
Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress - Aardvark Therapeutics ( NASDAQ:AARD )
Aardvark's IPO raised $94.2 million at $16/share; funds expected to support operations into 2027. HC Wainwright initiated coverage with Buy rating, sets $40 price forecast of AARD. Get ahead of Wall Street reactions-Benzinga Pro delivers signals, squawk, and news fast. Now 60% off this 4th of July.
Soleno Therapeutics Highlights New Data on VYKAT ( TM ) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., June 25, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) SLNO, a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today highlighted new data on VYKATTM XR ( diazoxide choline ) extended-release tablets, previously ...
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., June 20, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) SLNO, a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced one oral and six poster presentations at the 2025 United In Hope: International ...
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the Foundation for Prader-Willi Research, and the International Prader-Willi Syndrome Organisation Conference is the first-ever international meeting jointly hosted by the ...
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., May 22, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) SLNO, a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno's Marketing Authorization Application ( MAA ) seeking regulatory approval ...
